CTClaiborne W. Tydings

Claiborne W. Tydings

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claiborne W. Tydings has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan

    by Sarah J. Harmych, Neeraj Joshi, Hidenori Tanaka, Galina Bogatcheva, Marisol A. Ramirez, Ramona Graves-Deal, Claiborne W. Tydings, Marina T. Elia, Hunter R Lischwe Mueller, Isabella M. Silvestri, et al.


  • Open Access

    Computational structure prediction of lanthipeptides with NMR data reveals underappreciated peptide flexibility

    by Claiborne W. Tydings, Jens Meiler, Allison S. Walker

    Lanthipeptides are a class of thioether‐containing ribosomally synthesized and post‐translationally modified peptides, which often have antibiotic activity. As a potential starting point for therapeutics, interest in engineering lanthipeptides is growing. Our inability to computationally model and design lanthipeptides in molecular modeling and design software such as Rosetta limits our ability to rationally design lanthipeptides for drug discovery campaigns. We propose that implementing support for the lanthionine rings and dehydrated amino acids found in lanthipeptides will enable accurate lanthipeptide modeling with Rosetta. We find that when compared to the ensembles of lanthipeptides with NMR‐determined structures in the PDB, lanthipeptide ensembles generated with Rosetta have similar experimental agreement, lower Rosetta energy scores, and greater flexibility. Our use of ensemble‐averaged NOE distances instead of requiring individual structures to satisfy all NOE restraints was key for revealing the flexibility of these peptides. Our Rosetta lanthipeptide ensembles show increased flexibility in non‐cyclized peptide regions as well as increased lanthionine ring flexibility when internal hydrogen bonds are absent and glycine residues are present. Support for lanthipeptides in Rosetta enables the design and modeling of lanthipeptides in Rosetta for therapeutic development.


  • Open Access

    Hederagenin is a Highly Selective Antagonist of the Neuropeptide FF Receptor 1 that Reveals Mechanisms for Subtype Selectivity

    by Hannah Lentschat, Fabian Liessmann, Claiborne Tydings, Tina Schermeng, Jan Stichel, Nicole Urban, Michael Schaefer, Jens Meiler, Annette G. Beck‐Sickinger

    RF‐amide peptide receptors including the neuropeptide FF receptor 1 (NPFFR1) are G protein‐coupled receptors (GPCRs) that modulate diverse physiological functions. High conservation of endogenous ligands and receptors makes the identification of selective ligands challenging. Previously identified antagonists mimic the C‐terminus of peptide ligands and lack selectivity towards the closely related neuropeptide FF receptor 2 (NPFFR2) or the neuropeptide Y1 receptor (Y1R). In a high‐throughput screening, we identified the pentacyclic triterpenoid hederagenin (1) as a novel selective antagonist for the NPFFR1. Hederagenin (1) is a natural product isolated from Hedera helix (ivy). We characterized its mode of activity using in vitro and in silico methods, revealing an overlapping binding site of the small molecule with the orthosteric peptide agonists. Despite the high similarity of the orthosteric binding pockets of NPFFR1 and NPFFR2, hederagenin (1) shows strong subtype selectivity, particularly caused by slight differences in the shape of the binding pockets and the rigidity of the small molecule. Several residues inhibiting the activity of hederagenin (1) at the NPFFR2 were identified. As NPFFR1 antagonists are discussed as potential candidates for the treatment of chronic pain, these insights into the structural determinants governing subtype specificity will facilitate the development of next‐generation analgesics with improved safety and efficacy.


  • Open Access

    Hederagenin is a Highly Selective Antagonist of the Neuropeptide FF Receptor 1 that Reveals Mechanisms for Subtype Selectivity

    by Hannah Lentschat, Fabian Liessmann, Claiborne Tydings, Tina Schermeng, Jan Stichel, Nicole Urban, Michael Schaefer, Jens Meiler, Annette G. Beck‐Sickinger

    RF‐amide peptide receptors including the neuropeptide FF receptor 1 (NPFFR1) are G protein‐coupled receptors (GPCRs) that modulate diverse physiological functions. High conservation of endogenous ligands and receptors makes the identification of selective ligands challenging. Previously identified antagonists mimic the C‐terminus of peptide ligands and lack selectivity towards the closely related neuropeptide FF receptor 2 (NPFFR2) or the neuropeptide Y1 receptor (Y1R). In a high‐throughput screening, we identified the pentacyclic triterpenoid hederagenin (1) as a novel selective antagonist for the NPFFR1. Hederagenin (1) is a natural product isolated from Hedera helix (ivy). We characterized its mode of activity using in vitro and in silico methods, revealing an overlapping binding site of the small molecule with the orthosteric peptide agonists. Despite the high similarity of the orthosteric binding pockets of NPFFR1 and NPFFR2, hederagenin (1) shows strong subtype selectivity, particularly caused by slight differences in the shape of the binding pockets and the rigidity of the small molecule. Several residues inhibiting the activity of hederagenin (1) at the NPFFR2 were identified. As NPFFR1 antagonists are discussed as potential candidates for the treatment of chronic pain, these insights into the structural determinants governing subtype specificity will facilitate the development of next‐generation analgesics with improved safety and efficacy.


  • Open Access

    Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics

    by Claiborne W. Tydings, Bhuminder Singh, Adam W. Smith, Kaitlyn V. Ledwitch, Benjamin P. Brown, Christine M. Lovly, Allison S. Walker, Jens Meiler

    The epidermal growth factor (EGF) receptor (EGFR) is activated by the binding of one of seven EGF‐like ligands to its ectodomain. Ligand binding results in EGFR dimerization and stabilization of the active receptor conformation subsequently leading to activation of downstream signaling. Aberrant activation of EGFR contributes to cancer progression through EGFR overexpression/amplification, modulation of its positive and negative regulators, and/or activating mutations within EGFR. EGFR targeted therapeutic antibodies prevent dimerization and interaction with endogenous ligands by binding the ectodomain of EGFR. However, these antibodies have had limited success in the clinic, partially due to EGFR ectodomain resistance mutations, and are only applicable to a subset of patients with EGFR‐driven cancers. These limitations suggest that alternative EGFR targeted biologics need to be explored for EGFR‐driven cancer therapy. To this end, we analyze the EGFR interfaces of known inhibitory biologics with determined structures in the context of endogenous ligands, using the Rosetta macromolecular modeling software to highlight the most important interactions on a per‐residue basis. We use this analysis to identify the structural determinants of EGFR targeted biologics. We suggest that commonly observed binding motifs serve as the basis for rational design of new EGFR targeted biologics, such as peptides, antibodies, and nanobodies.